Drugs in tuberculosis and leprosy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

Original languageEnglish
Title of host publicationSide Effects of Drugs Annual
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Pages321-338
Number of pages18
ISBN (Print)9780128171639
DOIs
StatePublished - 2019

Publication series

NameSide Effects of Drugs Annual
Volume41
ISSN (Print)0378-6080

Fingerprint

Linezolid
bedaquiline
Rifamycins
Thioacetazone
Aminosalicylic Acid
Clofazimine
Cycloserine
Pyrazinamide
Dapsone
Ethambutol
Carbapenems
Fluoroquinolones
Macrolides
Isoniazid
Aminoglycosides
Leprosy
Toxicity
Tuberculosis
Health
Peptides

Keywords

  • Adverse effects
  • Ethambutol
  • Isoniazid
  • Leprosy
  • Pyrazinamide
  • Rifamycins
  • Side effect
  • Tuberculosis

Cite this

Ramanathan, M. R., Howell, C. K., & Sanders, J. M. (2019). Drugs in tuberculosis and leprosy. In S. D. Ray (Ed.), Side Effects of Drugs Annual (pp. 321-338). (Side Effects of Drugs Annual; Vol. 41). Elsevier B.V.. https://doi.org/10.1016/bs.seda.2019.08.010
Ramanathan, Meenakshi R. ; Howell, Crystal K. ; Sanders, James M. / Drugs in tuberculosis and leprosy. Side Effects of Drugs Annual. editor / Sidhartha D. Ray. Elsevier B.V., 2019. pp. 321-338 (Side Effects of Drugs Annual).
@inbook{7459939b9b5143458efd772909ff289d,
title = "Drugs in tuberculosis and leprosy",
abstract = "Tuberculosis (TB) remains a global health threat with approximately 25{\%} of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10{\%} of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.",
keywords = "Adverse effects, Ethambutol, Isoniazid, Leprosy, Pyrazinamide, Rifamycins, Side effect, Tuberculosis",
author = "Ramanathan, {Meenakshi R.} and Howell, {Crystal K.} and Sanders, {James M.}",
year = "2019",
doi = "10.1016/bs.seda.2019.08.010",
language = "English",
isbn = "9780128171639",
series = "Side Effects of Drugs Annual",
publisher = "Elsevier B.V.",
pages = "321--338",
editor = "Ray, {Sidhartha D.}",
booktitle = "Side Effects of Drugs Annual",

}

Ramanathan, MR, Howell, CK & Sanders, JM 2019, Drugs in tuberculosis and leprosy. in SD Ray (ed.), Side Effects of Drugs Annual. Side Effects of Drugs Annual, vol. 41, Elsevier B.V., pp. 321-338. https://doi.org/10.1016/bs.seda.2019.08.010

Drugs in tuberculosis and leprosy. / Ramanathan, Meenakshi R.; Howell, Crystal K.; Sanders, James M.

Side Effects of Drugs Annual. ed. / Sidhartha D. Ray. Elsevier B.V., 2019. p. 321-338 (Side Effects of Drugs Annual; Vol. 41).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Drugs in tuberculosis and leprosy

AU - Ramanathan, Meenakshi R.

AU - Howell, Crystal K.

AU - Sanders, James M.

PY - 2019

Y1 - 2019

N2 - Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

AB - Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

KW - Adverse effects

KW - Ethambutol

KW - Isoniazid

KW - Leprosy

KW - Pyrazinamide

KW - Rifamycins

KW - Side effect

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85073527868&partnerID=8YFLogxK

U2 - 10.1016/bs.seda.2019.08.010

DO - 10.1016/bs.seda.2019.08.010

M3 - Chapter

AN - SCOPUS:85073527868

SN - 9780128171639

T3 - Side Effects of Drugs Annual

SP - 321

EP - 338

BT - Side Effects of Drugs Annual

A2 - Ray, Sidhartha D.

PB - Elsevier B.V.

ER -

Ramanathan MR, Howell CK, Sanders JM. Drugs in tuberculosis and leprosy. In Ray SD, editor, Side Effects of Drugs Annual. Elsevier B.V. 2019. p. 321-338. (Side Effects of Drugs Annual). https://doi.org/10.1016/bs.seda.2019.08.010